How I manage patients with Wiskott Aldrich syndrome

Br J Haematol. 2019 May;185(4):647-655. doi: 10.1111/bjh.15831. Epub 2019 Mar 12.

Abstract

Wiskott Aldrich syndrome (WAS) is a primary immunodeficiency disease resulting in recurrent infections, eczema and microthrombocytopaenia. In its classical form, significant combined immune deficiency, autoimmune complications and risk of haematological malignancy necessitate early correction with stem cell transplantation or gene therapy. A milder form, X-linked thrombocytopaenia (XLT), shares similar bleeding risk from thrombocytopaenia but is not associated with other significant clinical features and is generally managed conservatively. Here, we detail our approach to the diagnosis and treatment of classical WAS and XLT.

Keywords: Wiskott Aldrich syndrome; X-linked thrombocytopenia; haematopoietic stem cell transplant; immunodeficiency.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Autoimmune Diseases / etiology
  • Conservative Treatment / methods
  • Eczema / etiology
  • Female
  • Genetic Techniques
  • Genetic Therapy / methods
  • Hematopoietic Stem Cell Transplantation / methods
  • Heterozygote
  • Humans
  • Infection Control / methods
  • Male
  • Mutation / genetics
  • Risk Factors
  • Thrombocytopenia / etiology
  • Thrombocytopenia / therapy
  • Wiskott-Aldrich Syndrome / diagnosis
  • Wiskott-Aldrich Syndrome / genetics
  • Wiskott-Aldrich Syndrome / therapy*